Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling

Prostate

Volumn 71, Issue 11, 2011, Pages 1158-1166

  Gan, Lu ^a   Wang, Jianlin ^a   Xu, Huibi ^a   Yang, Xiangliang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

chemotherapy sensitivity; docetaxel; p21; p38; p53

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DOCETAXEL; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; SYNAPTOPHYSIN;

APOPTOSIS; ARTICLE; CANCER CELL; DRUG EFFICACY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; P21-ACTIVATED KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TAXOIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79958228213     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21331     Document Type: Article

References (30)

1. Smith DC, Pienta KJ,. Paclitaxel in the treatment of hormone-refractory prostate cancer. Semin Oncol 1999; 26 (1 Suppl 2): 109-111. (Pubitemid 29153692)
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512. (Pubitemid 39315317)
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513-1520. (Pubitemid 39315318)
4. Gan L, Chen S, Wang YW, Watahiki A, Bohrer L, Sun Z, Wang Y, Huang H,. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009; 69 (21): 8386-8394.
5. Andreopoulou E, Muggia F,. Pharmacodynamics of tubulin and tubulin-binding agents: Extending their potential beyond taxanes. Clin Breast Cancer 2008; 8 (Suppl 2): S54-S60.
6. Torres K, Horwitz SB,. Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res 1998; 58 (16): 3620-3626. (Pubitemid 28376560)
7. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R,. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001; 20 (2): 147-155. (Pubitemid 32150260)
8. Wang LG, Liu XM, Kreis W, Budman DR,. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother Pharmacol 1999; 44 (5): 355-361. (Pubitemid 29455579)
9. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T,. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA 1997; 94 (18): 9679-9683. (Pubitemid 27408122)
10. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M,. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997; 57 (5): 870-874. (Pubitemid 27098011)
11. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L,. Taxol induction of p21WAFl and p53 requires c-raf-1. Cancer Res 1995; 55 (20): 4623-4626.
12. Thornton TM, Rincon M,. Non-classical p38 map kinase functions: Cell cycle checkpoints and survival. Int J Biol Sci 2009; 5 (1): 44-52.
13. Debes JD, Tindall DJ,. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351 (15): 1488-1490. (Pubitemid 39315314)
14. Grossmann ME, Huang H, Tindall DJ,. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001; 93 (22): 1687-1697. (Pubitemid 33130257)
15. Vousden KH, Lu X,. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2 (8): 594-604. (Pubitemid 37328926)
16. Greenblatt MS, Bennett WP, Hollstein M, Harris CC,. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54 (18): 4855-4878. (Pubitemid 24289415)
17. El-Deiry WS,. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003; 22 (47): 7486-7495. (Pubitemid 37487171)
18. Bree CV, Savonije JH, Franken NA, Haveman J, Bakker PJ,. The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells. Int J Oncol 2000; 16 (4): 739-744.
19. Lavarino C, Delia D, di Palma S, Zunino F, Pilotti S,. p53 in drug resistance in ovarian cancer. Lancet 1997; 349 (9064): 1556. (Pubitemid 27216387)
20. Reinecke P, Kalinski T, Mahotka C, Schmitz M, Déjosez M, Gabbert HE, Gerharz CD,. Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status. Cancer Lett 2005; 222 (2): 165-171. (Pubitemid 40603643)
21. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S,. The role of the p53 tumour suppressor gene in prostate cancer: A possible biomarker. Urology 1996; 48 (6): 971-979. (Pubitemid 127739005)
22. Brooks CL, Gu W,. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006; 21 (3): 307-315. (Pubitemid 43163526)
23. Craig AL, Blaydes JP, Burch LR, Thompson AM, Hupp TR,. Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation. Oncogene 1999; 18 (46): 6305-6312.
24. Shieh SY, Ikeda M, Taya Y, Prives C,. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91 (3): 325-334. (Pubitemid 27467963)
25. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M, Haupt Y,. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 1999; 18 (7): 1805-1814. (Pubitemid 29158524)
26. Liu S, Bishop WR, Liu M,. Differential effects of cell cycle regulatory protein p21WAF/Cip1 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Update 2003; 6 (4): 183-195. (Pubitemid 37129918)
27. Seidman R, Gitelman I, Sagi O, Horwitz SB, Wolfson M,. The role of ERK 1/2 and p38 MAP-kinase pathways in Taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res 2001; 268 (1): 84-92. (Pubitemid 32678863)
28. Shtil AA, Mandlekar S, Yu R, Walter RJ, Hagen K, Tan TH, Roninson IB, Kong AN,. Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene 1999; 18 (2): 377-384. (Pubitemid 29060613)
29. Stone AA, Chambers TC,. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 2000; 254 (1): 110-119. (Pubitemid 30066737)
30. Quan H, Xu Y, Lou L,. p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. Int J Cancer 2008; 122 (8): 1730-1737. (Pubitemid 351413418)